FDA Approves First Oral Carbapenem in U.S. History for Complicated Urinary Tract Infections

Tebipenem pivoxil (Utebzi) clears on PIVOT-PO noninferiority data — oral versus IV imipenem-cilastatin — opening a step-down path from hospital to outpatient for multidrug-resistant Enterobacteriaceae.

FDA & Regulatory Desk Saturday, 20 June 2026 · 2 min read

The U.S. Food and Drug Administration on June 17, 2026, approved tebipenem pivoxil hydrobromide (brand name: Utebzi) — the first oral carbapenem cleared for use in the United States — for the treatment of complicated urinary tract infections (cUTI), including pyelonephritis, in adults caused by susceptible Enterobacteriaceae.

PIVOT-PO Trial: Noninferiority, Not Superiority

Approval rested on the PIVOT-PO trial (NCT06059846), a Phase 3 randomized, controlled noninferiority study in adults with cUTI. Participants were assigned to tebipenem pivoxil 600 mg orally three times daily or imipenem-cilastatin 500 mg intravenously every six hours. The primary endpoint was overall response — a composite of clinical cure and microbiological eradication — at the test-of-cure visit approximately seven days after completing treatment, in the microbiological intent-to-treat (micro-ITT) population.

Overall response was 58.5% with oral tebipenem versus 60.2% with IV imipenem-cilastatin (adjusted difference: −1.3%, 95% CI −7.5% to +4.8%). The result satisfied the pre-specified noninferiority margin of −10 percentage points. The trial was not designed to establish superiority.

Regulatory Context and Prior CRL

The FDA issued a Complete Response Letter for an earlier tebipenem NDA in 2022, following the ADAPT-PO trial, which used ertapenem IV as the comparator. The agency raised adequacy concerns about that trial design. The program was subsequently refiled with PIVOT-PO data using imipenem-cilastatin IV as the comparator — a choice the FDA found sufficient to support approval.

Tebipenem pivoxil carries a QIDP (Qualified Infectious Disease Product) designation under the GAIN Act, granting priority review and a five-year market exclusivity extension. Its significance lies primarily in stewardship: it provides a step-down option for patients who require carbapenem-level coverage for multidrug-resistant Enterobacteriaceae, enabling a transition from intravenous to oral therapy and potentially shortening inpatient stays. The prescribing information includes a boxed warning on Clostridioides difficile–associated diarrhea and specifies use only when oral agents are appropriate and susceptibility testing confirms activity.

PIVOT-PO trial, ClinicalTrials.gov NCT06059846. FDA NDA 216592, June 17, 2026.

Correction — June 20, 2026: An earlier version of this article stated the FDA approved tebipenem pivoxil on June 20, 2026. The FDA acted on June 17, 2026, one day before the PDUFA target date of June 18; the GSK announcement confirming approval was issued the same day. All references have been corrected.

Trace · every claim, sourced

Reported and written by FDA & Regulatory Desk, then each load-bearing claim was bound to the primary source it rests on and checked out-of-band against that source before publication. The full mapping is below — nothing here is taken on faith.

The FDA on June 17, 2026, approved tebipenem pivoxil hydrobromide (Utebzi, NDA 216592) as the first oral carbapenem in the United States, indicated for complicated urinary tract infections in adults.

source on file

In PIVOT-PO (NCT06059846), overall response at test-of-cure was 58.5% with oral tebipenem versus 60.2% with IV imipenem-cilastatin; adjusted difference −1.3% (95% CI −7.5% to +4.8%), satisfying the −10 pp noninferiority margin.

source on file

After publication, a separate AI panel re-verifies every edition against these same sources. The running claim-confirmation rate and every correction are public on the accuracy ledger.

TopicsFDA